InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,615.95
(
-0.33%
)
US TECH 100
18,991.60
(
-1.09%
)
Dow Jones
41,221.40
(
0.11%
)
Brent Oil
80.50
(
2.71%
)
Bitcoin
63,563.71
(
-1.24%
)
Post# of 252975
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

WID

Send PM Follow Ignore
Followers 1
Posts 477
Boards Moderated 0
Alias Born 03/29/2007

WID

Re: anotherbiotechguy post# 58405

Thursday, 01/31/2008 12:08:15 PM

Thursday, January 31, 2008 12:08:15 PM

Post# of 252975
IDEV

The company's approved products consist of SANCTURA, a muscarinic receptor antagonist, and SANCTURA XR for the treatment of overactive bladder that are co-promoted with its partner Allergan, Inc.

SANCTURA XR was approved by the U.S. Food and Drug Administration (FDA) on August 3, 2007 and is available on the market in the U.S. as of January 2008. SANCTURA XR is currently being marketed jointly with Allergan, Inc.

Please make your comments, I appreciate your time and knowledge.

Disclosures: I am holding IDIX and MNTA.

Thanks a lot!
WID
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up